FDA Warning Causes Hospira to Issue Recall for the Second Time in Six Months
Drug maker Hospira, Inc. has issued a recall for two of its drugs for the second time in six months due to manufacturing defects. The U.S. Food and Drug Administration recently issued a warning about the defects, prompting the manufacturer to recall Propofol and Liposyn. Propofol, an anesthetic, and Liposyn, an intravenous nutritional product, were recalled April 1. Hospira told the FDA that these two pharmaceuticals had been contaminated with particulates during manufacturing.
The Lake Forest, Illinois based drug maker had previously recalled Propofol and Liposyn in October 2009 due to an equipment failure at one of their plants. The FDA inspected the Clayton, North Carolina manufacturing facility in January and February of this year. The FDA also reviewed the company’s plant in Rocky Mount, North Carolina in January and found a failure to validate processes used for manufacturing undisclosed products.
“We have been working closely with the FDA to find solutions to these problems,” said a Hospira spokesperson who said that the company is conducting “a comprehensive review of its manufacturing operations to ensure compliance with applicable regulations.”
California pharmaceutical litigation lawyer Samer Habbas places an emphasis on client education. To that end, he would like to remind his readers that the manufacturers of any product have a legal obligation to ensure that their products are safe to use. If someone is injured or killed using the product, the manufacturer may be liable for damages. If you or someone you love has been harmed by a defective drug, Southern California pharmaceutical litigation attorney Samer Habbas may be able to help. Mr. Habbas has the experience and resources to handle cases against large pharmaceutical companies and offers free consultations to discuss your case. To schedule your free consultation, call his law offices of samer habbas today at 888.848.5084.